Deferasirox induces mesenchymal-epithelial transition in crocidolite-induced mesothelial carcinogenesis in rats
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Asbestos was used worldwide in huge quantities in the past century. However, because of the unexpected carcinogenicity to mesothelial cells with an extremely long incubation period, many countries face this long-lasting social problem. Mesothelioma is often diagnosed in an advanced stage, for which no effective therapeutic protocols are yet established. We previously reported on the basis of animal experiments that the major pathology in asbestos-induced mesothelial carcinogenesis is local iron overload. Here, we undertook to find an effective strategy to prevent, delay, or lower the malignant potential of mesothelioma during asbestos-induced carcinogenesis. We used intraperitoneal injections of crocidolite to rats. We carried out a 16-week study to seek the maximal-tolerated intervention for iron reduction via oral deferasirox administration or intensive phlebotomy. Splenic iron deposition was significantly decreased with either method, and we found that Perls' iron staining in spleen is a good indicator for iron reduction. We injected a total of 10 mg crocidolite at the age of six weeks, and the preventive measures were via repeated oral administration of 25 to 50 mg/kg/d deferasirox or weekly to bimonthly phlebotomy of 4 to 10 mL/kg/d. The animals were observed until 110 weeks. Deferasirox administration significantly increased the fraction of less malignant epithelioid subtype. Although we found a slightly prolonged survival in deferasirox-treated female rats, larger sample size and refinement of the current protocol are necessary to deduce the cancer-preventive effects of deferasirox. Still, our results suggest deferasirox serves as a potential preventive strategy in people already exposed to asbestos via iron reduction. Cancer Prev Res; 6(11); 1222–30. ©2013 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is support for metals’ involvement in the biological effect of asbestos, with iron chelation therapy and phlebotomy demonstrating possible preventive effects against asbestos-induced carcinogenesis in animal models [5,6].”
From Asbestos and Iron (2023) · cites this paper as [5]
In the citing paper
“Pathogenicity of asbestos fibers has been associated with iron [4,[12], [13], [14]], as exemplified by asbestos body in histology [15].”
From Asbestos conceives Fe(II)-dependent mutagenic stromal milieu through ceaseless macrophage ferroptosis and β-catenin induction in mesothelium (2020) · cites this paper as [13]
In the citing paper
“Recently, we reported that deferasirox and deferoxamine revealed preventive effects on asbestos‐induced MM carcinogenesis in rats.26, 27”
From Phlebotomy as a preventive measure for crocidolite-induced mesothelioma in male rats (2018) · cites this paper as [26]
In the citing paper
“The levels of serum iron in females were conversely higher than males, confirming our previous study.26”
From Phlebotomy as a preventive measure for crocidolite-induced mesothelioma in male rats (2018) · cites this paper as [26]
In the citing paper
“A relatively low number of animals in each group is a limitation of this study, although these numbers have not been uncommon in phlebotomy studies.26, 28, 44”
From Phlebotomy as a preventive measure for crocidolite-induced mesothelioma in male rats (2018) · cites this paper as [26]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196 · cited 1×
“mesenchymal–epithelial transition, a reverse of epithelial– mesenchymal transition (28).”
BackgroundDonaldson, K., Murphy, F. A., Duffin, R., & Poland, C. A. (2010) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-7-5 · Cited by 916
Advances in Malignant Mesothelioma
Robinson, B. W. S., & Lake, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050152 · Cited by 889
Inflammation and EMT: an alliance towards organ fibrosis and cancer progression
López‐Novoa, J. M., & Nieto, M. A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900043 · Cited by 654
Role of iron in carcinogenesis: cancer as a ferrotoxic disease
Toyokuni, S. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2008.01001.x · Cited by 552 · cited 2×
“This is because generation of free radicals largely depends on catalytic iron (12, 13).”
BackgroundSelf-citationNagai, H., Okazaki, Y., Chew, S. H., Misawa, N., Yamashita, Y., Akatsuka, S., Ishihara, T., Yamashita, K., Yoshikawa, Y., Yasui, H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110013108 · Cited by 535
Self-citationIron-induced carcinogenesis: The role of redox regulation
Toyokuni, S. (1996) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(95)02111-6 · Cited by 471
Self-citationBody Iron Stores and the Risk of Cancer
Stevens, R. G., Jones, D. Y., Micozzi, M. S., & Taylor, P. R. (1988) · New England Journal of Medicine · doi:10.1056/nejm198810203191603 · Cited by 430
Zacharski, L. R., Chow, B. K., Howes, P. S., Shamayeva, G., Baron, J. A., Dalman, R. L., Malenka, D. J., Ozaki, C. K., & Lavori, P. W. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn209 · Cited by 230
Pathology of Asbestos-Associated Diseases
(2014) · doi:10.1007/978-3-642-41193-9 · Cited by 199
Research works printed but not linked: 1
- IARC, WHO, 2012, Asbestos (chrysotile, amosite, crocidolite, tremolite, actinolite, and anthophyllite). IARC monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens; part C: arsenic, metals, fibres, and dusts, 219
Cited by
Li, Z., Jiang, L., Chew, S. H., Hirayama, T., Sekido, Y., & Toyokuni, S. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101297 · Cited by 163
Self-citationToyokuni, S. (2016) · Pathology International · doi:10.1111/pin.12396 · Cited by 111
Self-citationMalignant mesothelioma as an oxidative stress-induced cancer: An update
Chew, S. H., & Toyokuni, S. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.05.002 · Cited by 102
Self-citationToyokuni, S. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.10.401 · Cited by 96
Self-citationFerroptosis in life: To be or not to be
Xu, L., Liu, Y., Chen, X., Zhong, H., & Wang, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114241 · Cited by 102
Metadata
- Authors
- Nagai, H., Okazaki, Y., Chew, S. H., Misawa, N., Yasui, H., & Toyokuni, S.
- Affiliations
- Kyoto Pharmaceutical University (JP)
- Venue
- Cancer Prevention Research
- Published
- 2013-11-01
- Volume
- 6
- Issue
- 11
- Pages
- 1222-1230
- ISSN
- 1940-6207 (ISSN-L)
- 1940-6215
- OpenAlex
- W2162660413
- Cited by
- 39
- References
- 31
- Citations by year
- 2025: 3 · 2023: 4 · 2022: 4 · 2021: 4 · 2020: 5 · 2019: 4 · 2018: 3 · 2017: 3 · 2016: 3 · 2015: 3 · 2014: 2 · 2013: 1
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Prevention Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science (24108008, 25860292)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Keywords
- deferasirox, crocidolite, asbestos, mesothelioma, mesenchymal-epithelial transition, iron overload, phlebotomy, iron reduction, cancer prevention, epithelioid subtype
- MeSH terms
- Deferasirox, Animals, Benzoates, Cell Transformation, Neoplastic, Female, Iron, Iron Chelating Agents, Male, Mesothelioma, Spleen, Triazoles, Asbestos, Crocidolite, Phlebotomy, Rats, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Deferasirox induces mesenchymal-epithelial transition in crocidolite-induced mesothelial carcinogenesis in rats. https://app.cochat.ai/papers/10.1158/1940-6207.capr-13-0244
- The paper
- Nagai, H., Okazaki, Y., Chew, S. H., Misawa, N., Yasui, H., & Toyokuni, S. (2013). Deferasirox induces mesenchymal-epithelial transition in crocidolite-induced mesothelial carcinogenesis in rats. Cancer Prevention Research. https://doi.org/10.1158/1940-6207.capr-13-0244
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.